• Explore /
  • Poster
  • / TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).

TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).

Abstract Video & Slides Poster

Authors

null

Samuel R. Denmeade

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Samuel R. Denmeade , Hao Wang , Harry Cao , Wei Fu , Ting Wang , Rehab Abdallah , Vanessa Bolejack , Neeraj Agarwal , David C. Smith , Michael Thomas Schweizer , Mark N. Stein , Vasily J. Assikis , Thomas W. Flaig , Russell Zelig Szmulewitz , Jeffrey Holzbeierlein , Channing Judith Paller , Michael Anthony Carducci , Mark Christopher Markowski , Mario A. Eisenberger , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02286921

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5517)

DOI

10.1200/JCO.2020.38.15_suppl.5517

Abstract #

5517

Poster Bd #

98

Abstract Disclosures

Similar Posters

First Author: Neal D. Shore

Poster

2022 ASCO Genitourinary Cancers Symposium

Survival of patients with metastatic prostate cancer and comorbid obesity.

Survival of patients with metastatic prostate cancer and comorbid obesity.

First Author: Nina Cheranda

First Author: Jamal Alamiri

First Author: Veronica Pereira Diaz